Skip to Main Content

Illumina, the dominant maker of machines to sequence DNA, is in talks to purchase Grail, a developer of a blood test to detect cancer that uses Illumina’s technology.

The discussions were first reported by Bloomberg News, and confirmed to STAT by a person with knowledge of the talks. The discussions could still fall apart at any time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.